The Novo Nordisk Haemophilia Foundation (NNHF) is a grant-making, non-profit organisation that strives to improve access to care for people with haemophilia and allied bleeding disorders in developing and emerging countries.
Haemophilia is a hereditary bleeding disorder affecting one in 10,000 people.1 75% of people with haemophilia live in the developing world2, where most do not have a diagnosis or access to adequate care.
Objective: Address the significant need for improving care for people with haemophilia and allied bleeding disorders in developing and emerging countries.
Vision: That all people with haemophilia or allied bleeding disorders receive care and treatment wherever they live
Geographical reach: Global
Partners: Local partners and international experts
Funded by: Novo Nordisk
Progress (as of December 2018):
Learn more: www.nnhf.org
Early in 2016, while 1,600 people were expected to be living with haemophilia in Malawi, diagnosis was not possible as the country was lacking public facilities and expertise to provide diagnosis and care.
1. World Federation of Hemophilia. What is hemophilia? Accessed 20. December 2018: https://www.wfh.org/en/page.aspx?pid=646.
2. UNCTAD. Handbook of Statistics 2017. Factsheet #17. Accessed 20. December 2018: https://unctad.org/en/PublicationChapters/tdstat42_FS11_en.pdf.